Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

(2018) Jan de Hoon et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

(2018) Christophe Depre et al.   HEADACHE

Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects

(2018) Ahmed N Mahmoud et al.   BMJ Open

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Erenumab (AMG 334) in episodic migraine

(2017) Messoud Ashina et al.   NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study

(2016) Dawn C. Buse et al.   HEADACHE

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

(2013) Marcelo E Bigal et al.   CEPHALALGIA

Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)

(2013) Andrew M. Blumenfeld et al.   HEADACHE

Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers

(2010) D C Buse et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY